Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 219.00 | |
50 mg | In stock | $ 396.00 | |
100 mg | In stock | $ 596.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 79.00 |
Description | MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively). |
Targets&IC50 | cdc42:78 nM, Ras 1/2/3:103 nM |
In vitro | MBQ-167 causes this phenotype in multiple mesenchymal cancer cell types including GFP-HER2-BM, MDA-MB-468, and Hs578t human breast cancer cells, as well as Mia-PaCa-2 pancreatic cancer cells, SKOV3 ovarian cancer cells, AGS and NCI-N87 gastric cancer cells, and SH-SY5Y neuroblastoma cells. MBQ-167 (≥100 nM) causes a loss of polarity in metastatic breast cancer cells. MBQ-167(500 nM; 24 h)treatment, results in ~95% cell rounding and detachment from the substratum in metastatic MDA-MB-231 cells. At earlier times (6h), MBQ-167(250 or 500 nM)treatment, induce an inhibition in Rac activity in the attached cell population, while the detached population demonstrates a ~40-50% inhibition. The attached population of MDA-MB-231 cells demonstrate a ~25% decrease in Rac activation while the detached cells are more responsive with a ~75% decrease following treatment with 250 nM MBQ-167 for 24 h . |
In vivo | Mice treated with MBQ-167 exhibited comparable doubling times for the treatments (10 and 11 days), and demonstrated a statistically significant decrease in tumor growth. Upon sacrifice, a dosage of 1.0 mg/kg body weight (BW) with MBQ-167 led to an approximate 80% reduction in tumor size, while a higher dose of 10 mg/kg BW achieved an approximate 95% reduction. In comparison, EHop-016 at a 10 mg/kg BW dosage resulted in about a 40% reduction in tumor growth, making MBQ-167 ten times more effective than EHop-016. |
Molecular Weight | 338.41 |
Formula | C22H18N4 |
CAS No. | 2097938-73-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 0.1 mg/mL (insoluble)
DMSO: 155 mg/mL (458.02 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MBQ-167 2097938-73-1 Cell Cycle/Checkpoint GPCR/G Protein MAPK CDK Ras Cyclin dependent kinase Inhibitor inhibit MBQ167 MBQ 167 inhibitor